Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitafloxacin vs doxycycline + rifampin for uncomplicated brucellosis
ChiCTR2300072703Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in brucellosis comparing Sitafloxacin monotherapy with Doxycycline + rifampin (2 arms). Primary endpoints: clinical response rates and therapeutic failure rates. Started Jul 2023; status: recruiting.
02
Drugs
sitafloxacindoxycyclinerifampicin
03
Conditions
brucellosis
Beyond the preview
Go deeper on ChiCTR2300072703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072703.